The inhibitory effect of rBCG on EB virus-positive tumours using an EB virus fusion gene
- 2 December 2021
- journal article
- research article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 106 (1) , 185-195
Abstract
At present, studies have found that latent Epstein-Barr virus (EBV) infection is associated with a variety of human tumours, and a vaccine is not available in this field. In this research, RT–PCR was used to obtain BZLF1 (immediately expressed early antigen Z) and LMP2 (latent membrane protein 2) cDNA from EBV. A ZLP2 fusion gene containing a linker sequence that encoded the polypeptide (Gly4Ser)3 was obtained using the sequence splicing overlap extension method. Then, ZLP2 was inserted into pMV261 cells, and the recombinant plasmid pMV-ZLP2 was transformed into BCG competent cells. After EB virus-positive tumour cell (NPRC18) cancer models were established with C57BL/6 J mice, tumour weight, tumour formation time and mouse survival conditions were analyzed, and flow cytometry was used to analyze the quantities of CD8 + and CD4 + T cells. HE staining was used to detect and analyze lymphocyte infiltration, and statistical analysis was used to analyze the immunological effect of recombinant BCG (rBCG). Compared with the control group, rBCG could significantly prolong the survival time of mice, slow tumour growth and delay tumour formation time. Recombinant BCG exhibits an obvious immune effect in mice and an inhibitory effect on EBV-positive cancer. Key points • AZLP2 fusion gene with BZLF1 and LMP2 of EB virus was constructed. • ZLP2 fusion gene was expressed with rBCG. • rBCG with ZLP2 has an obvious effect on EBV-positive cancer.Keywords
Funding Information
- Key Research and Development Plan project of Shandong (2018GCF118137)
This publication has 15 references indexed in Scilit:
- A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive CancerClinical Cancer Research, 2014
- Effective Treatment of Metastatic Forms of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive ImmunotherapyCancer Research, 2012
- Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcomaProtein & Cell, 2010
- The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladderCancer and Metastasis Reviews, 2009
- Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomasVirus Research, 2007
- Epstein‐Barr virus latent membrane 2A (LMP2A) down‐regulates telomerase reverse transcriptase (hTERT) in epithelial cell linesInternational Journal of Cancer, 2004
- RecombinantMycobacterium bovisbacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicityClinical and Experimental Immunology, 2004
- Epstein-Barr Virus LMP2A Interferes with Global Transcription Factor Regulation When Expressed during B-Lymphocyte DevelopmentJournal of Virology, 2003
- ZEB Negatively Regulates the Lytic-Switch BZLF1 Gene Promoter of Epstein-Barr VirusJournal of Virology, 2003
- New use of BCG for recombinant vaccinesNature, 1991